Comparison of oxybutynin and its active metabolite, N-desethyl- oxybutynin, in the human detrusor and parotid gland

Journal of Urology

Volumn 157, Issue 3, 1997, Pages 1093-1097

  Waldeck, Kristian ^a   Larsson, Bengt ^a   Andersson, Karl Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

bladder; N desethyl oxybutynin; oxybutynin; parotid gland

Indexed keywords

CARBACHOL; MUSCARINIC RECEPTOR; OXYBUTYNIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DETRUSOR MUSCLE; DRUG RECEPTOR BINDING; ELECTROSTIMULATION; FEMALE; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; MUSCLE CONTRACTION; NERVE STIMULATION; PAROTID GLAND; PRIORITY JOURNAL;

EID: 0031031716     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65148-6     Document Type: Article

References (19)

1. Yarker, Y. E., Goa, K. L. and Fitton, A.: Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging, 6: 243, 1995.
2. Andersson, K.-E.: Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol. Rev., 45: 253, 1993.
3. Wang, P., Luthin, G. R. and Ruggieri, M. R.: Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther., 273: 959, 1995.
4. Poli, E., Monica, B., Zappia, L., Pozzoli, C. and Bertaccini, G.: Antimuscarinic activity of telenzepine on isolated human urinary bladder: no role for M1-muscarinic receptors. Gen. Pharmacol., 23: 659, 1992.
5. Lindeke, B., Hallström, G., Johansson, C., Ericsson, Ö., Olsson, L.-I. and Strömberg, S.: Metabolism of oxybutynin: establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparations using deuterium substitution and gas chromatographic mass spectrometric analysis. Biomed. Mass. Spec., 8: 506, 1981.
6. Aaltonen, L., Allonen, H., Iisalo, E., Juhakoski, A., Kleimola, T. and Sellman, R.: Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol. Toxicol., 55: 100, 1984.
7. Hughes, K. M., Lang, J. C. T., Lazare, R., Gordon, D., Stanton, S. L., Malone-Lee, J. and Geraint, M.: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica, 22: 859, 1992.
8. 50) of an enzymatic reaction. Biochem. Pharmacol., 22: 3099, 1973.
9. Batra, S. Björklund, A., Hedlund, H. and Andersson K.-E.: Identification and characterization of muscarinic cholinergic receptors in the human urinary bladder and parotid gland. J. Auton. Nerv. Syst., 20: 129, 1987.
10. Atala, A. and Amin, M.: Current concepts in the treatment of genitourinary tract disorders in the older individual. Drugs Aging, 1: 176, 1991.
11. Nagy, F., Hamvas, A. and Frang, D.: Idiopathic bladder hyperactivity treated by Ditropan (oxybutynin chloride). Int. Urol. Nephrol., 22: 519, 1990.
12. Kachur, J. F., Peterson, J. S., Carter, J. P., Rzeszotarski, W. J., Hanson, R. C. and Noronha-Blob, L.: R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J. Pharmacol. Exp. Ther., 247: 867, 1988.
13. Tonini, M., Rizzi, C. A. and Perucca, E.: Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle. J. Pharm. Pharmacol., 39: 103, 1987.
14. Malkowicz, S. B., Wein, A. J., Ruggieri, M. R. and Levin, R. M.: Comparison of calcium antagonist properties of antispasmotic agents. J. Urol., 138: 667, 1987.
15. Nilvebrant, L., Andersson, K.-E. and Mattiasson, A.: Characterization of the muscarinic cholinoceptors in the human detrusor. J. Urol., 134: 418, 1985.
16. Douchamps, J., Derenne, F., Stockis, A., Gangji, D., Juvent, M. and Herchuelz, A.: The pharmacokinetics of oxybutynin in man. Eur. J. Clin. Pharmacol., 35: 515, 1988.
17. Enzelsberger, H., Helmer, H. and Kurz, C.: Intravesical instillation of oxybutynin in woman with idiopathic detrusor instability: a randomised trial. Br. J. Obstet. Gynaecol., 102: 929, 1995.
18. Madersbacher, H. and Knoll, M.: Intravesical application of oxybutynin: mode of action in controlling detrusor hyperreflexia. Eur. Urol., 28: 340, 1995.
19. Massad, C. A., Kogan, B. A. and Trigo-Rocha, F. E.: The pharmacokinetics of intravesical and oral oxybutynin chloride. J. Urol., 148: 595, 1992.